Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis

This publication has 26 references indexed in Scilit:

• Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
  New England Journal of Medicine, 2001
• The Gene Polymorphism of Tumor Necrosis Factor-β, But Not That of Tumor Necrosis Factor-α, Is Associated With the Prognosis of Sarcoidosis
  Chest, 2001
• POLYMORPHISMS AT POSITION −308 IN THE PROMOTER REGION OF THE TNF-α AND IN THE FIRST INTRON OF THE TNF-β GENES AND SPONTANEOUS AND LIPOPOLYSACCHARIDE-INDUCED TNF-α RELEASE IN SARCOIDOSIS
  Cytokine, 1999
• A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate
  New England Journal of Medicine, 1999
• PATHOLOGY OF SARCOIDOSIS
  Clinics in Chest Medicine, 1997
• IMMUNOLOGY OF SARCOIDOSIS
  Clinics in Chest Medicine, 1997
• TUMOUR NECROSIS FACTOR ALPHA PROMOTER GENE POLYMORPHISM IN SARCOIDOSIS
  Cytokine, 1997
• OXPENTIFYLLINE IN ENDOTOXAEMIA
  The Lancet, 1989
• The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection
  Cell, 1989
• Course and prognosis of sarcoidosis in a nonreferral setting. Analysis of 86 patients observed for 10 years
  The American Journal of Medicine, 1985